Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Everolimus with Paclitaxel and Trastuzumab in HER2+ Breast Cancer
NCT01163929Phase 2Withdrawn
- Sponsor
- University of Kansas
- Start
- Jul 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of everolimus in HER2-positive breast cancer, sponsored by University of Kansas. Planned start Jul 2010; status: withdrawn.
02
Drugs
everolimus
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01163929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163929.